Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer
- PMID: 29302695
- PMCID: PMC5885163
- DOI: 10.1001/jamaoncol.2017.4504
Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer
Abstract
Importance: Combined-modality therapy with chemotherapy and radiation therapy plays a crucial role in the upfront treatment of patients with limited-stage small cell lung cancer (SCLC), but there may be barriers to utilization in the United States.
Objective: To estimate utilization rates and factors associated with chemotherapy and radiation therapy delivery for limited-stage SCLC using the National Cancer Database.
Design, setting, and participants: Analysis of initial management of all limited-stage SCLC cases from 2004 through 2013 in the National Cancer Database.
Main outcomes and measures: Utilization rates of chemotherapy and radiation therapy at time of initial treatment. Multivariable analysis identified independent clinical and socioeconomic factors associated with utilization and overall survival.
Results: A total of 70 247 cases met inclusion criteria (55.3% female; median age, 68 y [range, 19-90 y]). Initial treatment was 55.5% chemotherapy and radiation therapy, 20.5% chemotherapy alone, 3.5% radiation therapy alone, and 20.0% neither (0.5% not reported). Median survival was 18.2 (95% CI, 17.9-18.4), 10.5 (95% CI, 10.3-10.7), 8.3 (95% CI, 7.7-8.8), and 3.7 (95% CI, 3.5-3.8) months, respectively. Being uninsured was associated with a lower likelihood of both chemotherapy (odds ratio [OR], 0.65; 95% CI, 0.56-0.75; P < .001) and radiation therapy (OR, 0.75; 95% CI, 0.67-0.85; P < .001) administration on multivariable analysis. Medicare/Medicaid insurance had no impact on chemotherapy use, whereas Medicaid (OR, 0.79; 95% CI, 0.72-0.87; P < .001) and Medicare (OR, 0.86; 95% CI, 0.82-0.91; P < .001) were independently associated with a lower likelihood of radiation therapy delivery. Lack of health insurance (HR, 1.19; 95% CI, 1.13-1.26; P < .001), Medicaid (HR, 1.27; 95% CI, 1.21-1.32; P < .001), and Medicare (HR, 1.12; 95% CI, 1.09-1.15; P < .001) coverage were independently associated with shorter survival on adjusted analysis, while chemotherapy (HR, 0.55; 95% CI, 0.54-0.57; P < .001) and radiation therapy (HR, 0.62; 95% CI, 0.60-0.63; P < .001) were associated with a survival benefit.
Conclusions and relevance: Substantial proportions of patients documented in a major US cancer registry did not receive radiation therapy or chemotherapy as part of initial treatment for limited-stage SCLC, which, in turn, was associated with poor survival. Lack of radiation therapy delivery was uniquely associated with government insurance coverage, suggesting a need for targeted access improvement in this population. Additional work will be necessary to conclusively define exact population patterns, specific treatment deficiencies, and causative factors leading to heterogeneous care delivery.
Conflict of interest statement
Figures
Comment in
-
Underutilization of Combined-Modality Therapy in Limited-Stage Small Cell Lung Cancer-Reply.JAMA Oncol. 2018 Oct 1;4(10):1436-1437. doi: 10.1001/jamaoncol.2018.3292. JAMA Oncol. 2018. PMID: 30073269 No abstract available.
-
Underutilization of Combined-Modality Therapy in Limited-Stage Small Cell Lung Cancer.JAMA Oncol. 2018 Oct 1;4(10):1435-1436. doi: 10.1001/jamaoncol.2018.3261. JAMA Oncol. 2018. PMID: 30073331 No abstract available.
Similar articles
-
Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer.JAMA Netw Open. 2020 Apr 1;3(4):e203277. doi: 10.1001/jamanetworkopen.2020.3277. JAMA Netw Open. 2020. PMID: 32320035 Free PMC article.
-
Association of Insurance and Community-Level Socioeconomic Status With Treatment and Outcome of Squamous Cell Carcinoma of the Pharynx.JAMA Otolaryngol Head Neck Surg. 2017 Sep 1;143(9):899-907. doi: 10.1001/jamaoto.2017.0837. JAMA Otolaryngol Head Neck Surg. 2017. PMID: 28662244 Free PMC article.
-
Effect of Thoracic Radiotherapy Timing and Fractionation on Survival in Nonmetastatic Small Cell Lung Carcinoma.Clin Lung Cancer. 2017 Mar;18(2):207-212. doi: 10.1016/j.cllc.2016.07.009. Epub 2016 Aug 8. Clin Lung Cancer. 2017. PMID: 27686970
-
Treatment of extensive-stage small cell lung carcinoma: current status and future prospects.Eur Respir J. 2010 Jan;35(1):202-15. doi: 10.1183/09031936.00105009. Eur Respir J. 2010. PMID: 20044461 Review.
-
Multimodality Therapy for Limited-Stage Small-Cell Lung Cancer.J Oncol Pract. 2016 Feb;12(2):111-7. doi: 10.1200/JOP.2015.009068. J Oncol Pract. 2016. PMID: 26869647 Review.
Cited by
-
Survival among lung cancer patients: comparison of the U.S. military health system and the surveillance, epidemiology, and end results (SEER) program by health insurance status.Cancer Causes Control. 2024 Jan;35(1):21-31. doi: 10.1007/s10552-023-01765-0. Epub 2023 Aug 2. Cancer Causes Control. 2024. PMID: 37532916
-
Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study.BMJ Open. 2023 Feb 6;13(2):e052556. doi: 10.1136/bmjopen-2021-052556. BMJ Open. 2023. PMID: 36746549 Free PMC article.
-
Identification of the effects of COVID-19 on patients with pulmonary fibrosis and lung cancer: a bioinformatics analysis and literature review.Sci Rep. 2022 Sep 26;12(1):16040. doi: 10.1038/s41598-022-20040-x. Sci Rep. 2022. PMID: 36163484 Free PMC article. Review.
-
Small cell lung cancer in young patients: trends in sociodemographic factors, diagnosis, treatment, and survival.J Thorac Dis. 2022 Aug;14(8):2880-2893. doi: 10.21037/jtd-22-210. J Thorac Dis. 2022. PMID: 36071763 Free PMC article.
-
Sequential Hypofractionated versus Concurrent Twice-Daily Radiotherapy for Limited-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis.Cancers (Basel). 2022 Aug 13;14(16):3920. doi: 10.3390/cancers14163920. Cancers (Basel). 2022. PMID: 36010913 Free PMC article.
References
-
- Ganti AK, Zhen W, Kessinger A. Limited-stage small-cell lung cancer: therapeutic options. Oncology (Williston Park). 2007;21(3):-. - PubMed
-
- Micke P, Faldum A, Metz T, et al. . Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease? Lung Cancer. 2002;37(3):271-276. - PubMed
-
- Almquist D, Mosalpuria K, Ganti AK. Multimodality therapy for limited-stage small-cell lung cancer. J Oncol Pract. 2016;12(2):111-117. - PubMed
-
- Thomas CR Jr, Giroux DJ, Janaki LM, et al. . Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancer. Lung Cancer. 2001;33(2-3):213-219. - PubMed
-
- Perry MC, Eaton WL, Propert KJ, et al. . Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med. 1987;316(15):912-918. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous